中国肿瘤生物治疗杂志2023，Vol.30Issue(11)：981-986,6.DOI:10.3872/j.issn.1007-385x.2023.11.007
扶正方药对晚期NSCLC患者外周血可溶性免疫检查点蛋白分子水平的影响及其临床意义
Effect of Fuzheng formulas on the level of soluble immune checkpoint protein molecules in peripheral blood of patients with advanced NSCLC and its clinical significance
摘要
Abstract
Objective:To observe the effect of Fuzheng formulas on the peripheral blood levels of 12 soluble immune checkpoint molecules in patients with advanced non-small cell lung cancer(NSCLC)treated with third-line therapy,and to analyze the relationship between the baseline level of soluble immune checkpoints and the progression-free survival(PFS)of NSCLC patients.Methods:A total of 72 patients with advanced NSCLC who received third-line treatment(Fuzheng formulas combined with standard Western medicine treatment regimen)in the Department of Oncology,Longhua Hospital from October 2020 to April 2023 were enrolled.The LEGENDplexTM multi-factor kit was used to detect the expression level of soluble immune checkpoint molecules before and after 4 cycles of treatment,and the correlation between their baseline levels and PFS prognosis was analyzed.Results:After 4 cycles of treatment,sCD137,sTGF-β1,sPD-L1,sPD-L2 and other indicators were significantly decreased(P<0.05 or P<0.01).Kaplan-Meier survival analysis showed that the PFS of patients with high sPD-L2 level was shorter than that of patients with low sPD-L2 level(P<0.05).COX multivariate analysis showed that sPD-L2 expression level was an independent impact factor for PFS in advanced NSCLC patients treated with third-line therapy(P<0.05).Conclusion:Fuzheng formulas have a certain regulatory effect on the levels of soluble immune checkpoint molecules.A high level of sPD-L2 indicates shorter PFS in patients with advanced NSCLC,and sPD-L2 may be an independent impact factor for PFS in advanced NSCLC patients undergoing third-line treatment.关键词
扶正方药/可溶性免疫检查点蛋白/晚期非小细胞肺癌/预后因子Key words
Fuzheng formulas/soluble immune checkpoint protein/advanced non-small cell lung cancer/prognostic factor分类
医药卫生引用本文复制引用
刘芳芳,姜怡,蔡雨晴,刘苓霜..扶正方药对晚期NSCLC患者外周血可溶性免疫检查点蛋白分子水平的影响及其临床意义[J].中国肿瘤生物治疗杂志,2023,30(11):981-986,6.基金项目
国家自然科学基金(No.82374533) （No.82374533）
上海市自然科学基金项目(No.21ZR1463700) （No.21ZR1463700）
上海市卫生健康委员会卫生行业临床研究专项(No.202140370) （No.202140370）
